FDA Approves Genglycos, First Gene Therapy for Glycogen Storage Disease Type 1a

The FDA approved Genglycos, the first gene therapy for glycogen storage disease type 1a (GSD1a), providing a new treatment that reduces reliance on cornstarch intake for patients. This accelerated approval signals potential long-term health benefits pending further research, but requires careful management of side effects and hygiene precautions.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 19 Aug 2026 and 22 Aug 2026.